Introduction
In situ follicular lymphoma (FL), initially reported in 2002, was defined as lymph nodes (or other lymphoid proliferations) with an intact architecture but with scattered germinal centers (GC) with variably dense populations of BCL2+ CD10+ lymphoid cells that are usually predominantly centrocytes, are monoclonal and have a t(14;18) IGH/BCL2 translocation. 1 While the individual abnormal follicles are indistinguishable from those in a FL, these cases are considered important to recognize because a significant proportion of the patients do not have concurrent or subsequent overt FL. In situ FL was recognized as a FL variant in the 2008 WHO classification, and because of concern that they were not an overt lymphoma, the name "intrafollicular neoplasia" was introduced as optional diagnostic terminology. More recently, the name of "follicular lymphoma-like B-cells of uncertain or undetermined significance" (FLBUS), was suggested to emphasize that these cases are not considered overt malignant lymphomas. 2, 3 A number of important uncertainties still remain, in part because of very few published studies with inconsistent results and, in part, because the criteria for recognizing these cases has evolved. The initial report suggested that 44% of patients would have an associated FL including 23% who developed a FL, and a small study from another group reported an associated FL or diffuse large B-cell lymphoma in 38% including the 2/13 (15%) patients with subsequent FL or DLBCL. 1, 4 The latter series also reported only 38% of cases with no lymphoma at all as several patients had lymphomas not of FL/DLBCL type. 4 Subsequently, a report from the initial group 5 distinguished in situ FL from "partial nodal involvement by FL"
(PFL), recategorized some of their original cases and added new cases, then finding that 18%
of the patients had a prior or concurrent FL and only 5% developed a subsequent FL. Some patients also had other types of B-cell lymphoma. An even more recent small study from other investigators, found synchronous (6) or subsequent (2) B-cell lymphomas in 61% of cases with in situ FL. 6 In addition to uncertainties concerning the incidence of associated overt lymphomas, whether the extent of FLBUS can be used to predict which cases will be associated with an overt lymphoma is also controversial. 4, 5 It is totally unknown how often flow cytometric immunophenotypic studies (FCS) will detect FLBUS. This is an important question given the heavy reliance on cytopathologic diagnostic procedures to evaluate lymphadenopathy since the presence of a population of cells with a FL-like phenotype is often used to support the diagnosis of a FL or one of the other GC-associated lymphoid neoplasms. Finally, because the proportion of overt FL preceded by FLBUS is unknown, it remains to be established whether the situation is analogous to that with chronic lymphocytic leukemia where virtually all cases are preceded by monoclonal B-cell lymphocytosis. 7 To address these questions, 31 cases of FLBUS were investigated including quantitative assessment of the FL-like follicles and the results correlated with the clinical findings. In addition, FCS had been performed in 17 cases. Four cases of overt FL were also identified in which a prior "benign" lymph node biopsy could be obtained and stained looking for FLBUS.
Methods

Case selection, pathologic and clinical review
The study was performed in accordance with the guidelines of the Institutional Review 
Cytogenetic FISH studies
Cytogenetic FISH studies were performed on paraffin sections in the 3 concurrent and one subsequent DLBCL, as previously described 9 , using the following probes: Vysis LSI BCL6 dual--color break apart and Vysis LSI BCL2 dual--color break apart (Abbot Molecular, Des
Plaines, IL).
Retrospective analysis of "benign" lymphoid tissue in patients with a subsequent overt FL Lymph node biopsies that had been considered benign were identified in 4 patients with a subsequent overt FL. The histologic sections were reviewed and, unless already available, CD10, BCL2, CD3 and CD20 immunohistochemical stains were performed and reviewed. One other case was reviewed but excluded as a remote history of prior FL was mentioned although there was no documentation of it in our system.
Statistics and imaging
Numerical variables were compared with the Mann Whitney U test using GraphPad Prism 5 software (Graph Pad Software, La Jolla, CA). Photomicrographs were acquired with an Olympus DP71 camera and software (Olympus America Inc) mounted on an Olympus BX51 microscope. Images were finalized with Adobe Photoshop CS4 extended.
Results
Clinical Features and Association with Other Lymphomas
Most cases occurred in older adults (38-88 yrs, median 72 yrs) with a male:female ratio of 2.1:1 (Table 1) were observed and treatment data was unknown in one. All were alive after a median follow-up of 11 months (3-71 mo.). In addition, there were 6 patients with prior or concurrent non-GC derived B-cell or T-cell lymphomas, 2 of whom died (#4 and #19, both with concurrent CLL/SLL) (median follow-up 31 mo., 2-66). The single patient who developed gastric DLBCL died in 1 month after the FLBUS diagnosis shortly after the DLBCL was diagnosed.
Histopathologic / Immunophenotypic features of FLBUS and correlation with clinical findings
Except in cases with concurrent involvement by a secondary lymphoma, all cases showed architectural preservation with a median of 34 (3-916) usually small to medium sized GC in the tissue examined ( Fig. 1) . The median density of GC was 49/cm 2 (2-331). Mantle zones were unremarkable in 22/31 cases but were expanded in 8 and attenuated in 1. BCL2+ cells in the germinal centers in all cases showed greater intensity of staining compared to the mantle zones ( Fig. 1) . In 2/31 cases the intensity of the BCL2+ cells in some GC was decreased compared to other BCL2+ GC. BCL2+ GC areas in all cases were composed almost exclusively of centrocytes.
The biopsies with FLBUS demonstrated from 1-207 BCL2+ GC ( median 10) with no significant differences between the 11 cases with (median 17, range 2-115) and 20 cases without an associated FL or DLBCL (9, 1-207) ( Table 2 , Fig. 2A ). In addition, neither the proportion (median 67% vs 68%) nor the density (21 follicles/cm 2 for both groups) of BCL2+ GC showed significant differences between these 2 groups ( Table 2 , Fig. 2B ). Significant differences were also not found between the 2 groups based on the extent of involvement of individual follicles (not all data shown, Table 2 , Fig. 3 ) or the density of BCL2 positive follicles (Fig. 4) . Further subset analysis of these parameters for the FL/DLBCL cases with a history of prior FL compared to those cases with a concurrent FL or DLBCL also were not significantly different. Similar results were obtained when the FL and DLBCL cases were compared separately with the 20 cases without an associated FL or DLBCL.
Flow cytometric immunophenotypic studies (FCS)
FCS showed CD10+ light chain class restricted (LCCR) B-cells in 7/15 tested cases with FLBUS ( Fig. 5 and Table 3 ). In addition, 1 case had demonstrable CD10+ BCL2+ cells that 
Cytogenetic FISH studies
Cytogenetic FISH studies for BCL2 and BCL6 translocations were performed in the 4 available biopsies with concurrent (3) or subsequent DLBCL (1) (table 4). Only one case showed a possible BCL2 translocation.
Retrospective analysis of prior "benign" lymph node biopsies
Four "benign" LN biopsies were identified that had been performed 1-108 months (median 27 mo.) prior to the diagnosis of an overt FL. The clinicopathologic features are described in Table 5 . All cases showed an intact architecture. BCL2+ CD10+ GCs were detected in all cases. The LN in the positive cases showed prominent GC in 2, and only occasional GC in the other 2 ( Fig. 6 ). Although not evaluable in one case because of limited tissue on the BCL2 stain, the absolute number of BCL2+ GC was low and they were variable in size.
FCS had been performed in only 1 case. They demonstrated approximately 1% CD10+, CD20+, BCL2+, kappa restricted B cells out of a total of about 45% otherwise polytypicappearing B-cells with a κ/λ ratio of about 1.0 (some non-specific staining complicated interpretation).
Discussion
In situ localization of FL, soon after shortened to in situ FL, was initially described in 2002 as the presence of focal germinal centers (GC) with CD10+, strongly BCL2+ monoclonal centrocytes in lymph nodes that otherwise had an intact architecture and follicular hyperplasia 1 .
These authors emphasized how almost half of the cases represented early involvement of reactive GCs by FL, how the other cases might either be very early FL or a preneoplastic event and finally how immunohistochemistry was useful for "early diagnosis." Surprisingly, there have only been a limited number of studies published over the subsequent decade in spite of the fact that these cases were included as a variant of FL in the 2008 WHO classification of lymphomas as in situ FL/intrafollicular neoplasia. 10 Subsequently, in order to emphasize the fact that these are not considered to be overt lymphomas, the name of follicular lymphoma-like B-cells of uncertain or undetermined significance (FLBUS) has been suggested. 2, 3 Consistent with the interest in not overdiagnosing lymphomas leading to patient anxiety and potential overtreatment, the reported apparent incidence of FLBUS is much greater than the incidence of FL (2.3% versus approximately 0.03%). 11, 12 In 2011, the original group of authors published a second overlapping series of in situ FL where they refined their criteria and introduced the distinction from partial involvement by FL. 14 Excluding PFL from in situ FL led to a fall in the proportion of patients developing subsequent FL from 23% to 5% although another 18% of the patients did have a prior or concurrent FL. 5 Another study of only 13 cases of FLBUS reported the presence of an associated FL or DLBCL in 38% of patients including the 15% of patients who developed a subsequent FL or DLBCL. 4 The most recent study of 13 patients with in situ FL, reported synchronous (6) or subsequent (2) B-cell lymphomas in 61% of cases. 6 Given this high proportion of cases associated with other mostly clonally related B-cell lymphomas, these authors emphasized how "follicular lymphoma in situ" "might represent a phenomenon related to follicular homing of lymphoma, rather than being an attribute of preneoplastic FL precursors." 6 Although in most other studies the clonal relationship between the FLBUS and the associated overt lymphomas is unknown, there are other rare reports that they can represent the same clone including one demonstrating secondary chromosomal abnormalities restricted to the overt lymphoma. 15, 16 It should be recognized that, particularly when FLBUS is found in a patient with a prior documented FL, whether one has discovered a new or pre-existing preneoplastic population or subtle involvement by an overt lymphoma cannot be determined at the current time. Even clonal identity does not answer this question. Whether the presence of additional molecular/cytogenetic abnormalities could provide an answer remains to be determined.
Studies assessing the relationship of FLBUS to associated overt B-cell lymphomas are difficult because of the paucity and focality of the abnormal cells in FLBUS and possibly biased to cases with more extensive involvement.
Consistent with the concept that FLBUS shows a slow rate of progression, only one patient in this series without an associated prior or concurrent FL or DLBCL developed a subsequent FL or DLBCL. It should be acknowledged, however, that the follow-up period in this and other studies remains relatively short and that the ultimate proportion of patients who will progress remains to be determined. On the other hand, more than half of the patients in this series and in two others had either synchronous or metachronous overt lymphomas of some type. 4, 6 Because many patients with FLBUS do have prior or concurrent FL or other types of lymphoma, as also emphasized by others, 4, 6 staging is important. However, with the diagnosis of FLBUS and no evidence of overt lymphoma elsewhere, our findings further support the recommended concept of conservative management with routine follow-up. 17 It is important to also recognize, however, that disseminated FLBUS is not equivalent to the presence of an overt lymphoma. One of the patients reported here had recurrent FLBUS, FLBUS has been reported to be present at two separate anatomic sites 18, 19 and nodal FLBUS with clonally identical cells in the peripheral blood have been described. 20 This concept is also consistent with the observation that up to 66% of healthy individuals older than 10 years have circulating cells with BCL2 translocations and the belief that these cells already have many FL-like features and colonize the GC niche.
21-27
Other non-FL/DLBCL B-cell, T-cell and classical Hodgkin type lymphomas have also been reported in 15 -31% of patients with FLBUS; however, whether these bear any relationship to the FLBUS, reflect an increased propensity to develop lymphoma due to genetic or environmental factors or simply result from the overt neoplasm leading to a tissue biopsy are all unknown. 4, 5 Here there were 4 non-FL/DLBCL B-cell lymphomas, 3 T-cell lymphomas and 2 cases of classical Hodgkin lymphoma seen in a total of 8 patients (26%). Clonal relationships between FL and classical Hodgkin lymphomas and FL and mantle cell lymphoma (MCL) occurring in the same patient have been reported, so that there still could be a clonal relationship between FLBUS and some of these other types of lymphoma. [28] [29] [30] [31] While the cases of DLBCL are much more likely to be related to a pre-existing FL or FLBUS, the FISH findings in this study suggested that at least most did not represent transformation of the FLBUS, most of which will have BCL2 translocations. 4, 5 Others have reported presumptive clonal identity between the FLBUS and the associated higher grade B-cell lymphomas based on PCR product size. 6 Definitive comparisons would require sequencing of the PCR products. but the larger study of Jegalian, et al, who used a simpler scoring system found no significant association. 5 In the latter study 6 of the 7 cases with an associated FL fell into the category with the least involvement whereas only 6/20 cases with no associated lymphoma did. 5 Our study examined in even greater detail the absolute number of involved follicles, their proportion, and the degree of involvement within individual follicles and added the parameter of density of abnormal follicles, but found that none of these parameters could predict the presence of an associated DLBCL, FL or FL/DLBCL. As in the other studies, it is important to remember that this data is still based on a limited number of patients with a relatively short follow-up time.
FLBUS is typically identified based on immunohistochemical staining of tissue sections.
Currently, however, more and more patients are being evaluated using needle core biopsies or even fine needle aspiration leading to greater reliance on flow cytometric immunophenotypic studies (FCS). Currently the interpretation of finding CD10+ light chain restricted B-cells or CD10+ BCL2+ B-cells is that it reflects a B-cell lymphoma of germinal center origin with the major exception being the rare cases of clonal follicular hyperplasias which are most typically seen in children and young adults. 32 The proportion of FLBUS that will be identified by FCS which would then require additional disclaimers when interpreting "positive" FCS, is completely unknown. Whereas, the focality of FLBUS might suggest a low proportion of cases being detected, the ability of FCS to focus on very specific lymphoid populations even if very small, suggests the possibility of a higher yield. FCS detected CD10 positive light chain restricted and/or BCL2 positive B-cells in about half of our cases. While the overall proportion of these cells was relatively low, they often made up a high proportion of the CD10+ B-cells present. As might be expected, these cases were found to have a significantly higher proportion of BCL2+ follicles. A CD10+ BCL2+ B-cell population was detected in all tested cases with CD10 positive light chain restricted cells and also in an additional biopsy that had a CD10+ but surface immunoglobulin negative population. These results indicate that detection of CD10+ BCL2+
and/or light chain restricted cells in FCS should be interpreted with even greater caution now, since in addition to all the other necessary disclaimers, the possibility of FLBUS, currently considered to be very different from even a low grade FL, must be raised. Conversely, about half of FLBUS were missed in the FCS, not all of which had BCL2 studies and with sampling issues a possible explanation.
Finally, other than a recently published abstract that reported finding in situ FL preceding overt FL in 6/8 cases (with the other 2 cases demonstrating undiagnosed overt FL)
unpublished data mentioned in a study of MCL that describes finding in situ FL preceding overt FL in only 16% of cases 34 , it is unknown how often overt FL is preceded by FLBUS. Our findings support that FLBUS is a precursor of at least most FL, although this does not mean that focal follicular involvement by an overt FL might not mimic FLBUS in some cases. It is of interest that the only case where we did not find FLBUS preceding the FL was a case that was subsequently excluded from this study because it actually represented a primary cutaneous follicle center lymphoma, an entity considered distinct from other FL in the 2008 WHO classification. This is analogous to the situation with chronic lymphocytic leukemia (CLL)/monoclonal B-cell lymphocytosis (MBL) and possibly MCL/MCLBUS. MBL of CLL type has a rate of progression to CLL of only 1-2%/year; [35] [36] [37] [38] however, almost all CLL are preceded by MBL. 7 The situation may be similar with MCLBUS, although the proportion of MCL with preceding in situ MCL or small foci of cyclin D1+ lymphoid cells is controversial. 34, 39, 40 This multiparameter study therefore demonstrates that FLBUS has a low rate of progression to overt lymphomas, at least in the several years following diagnosis, but which is associated in about half the cases with a synchronous or metachronous overt FL, DLBCL or other type of malignant lymphoma. In about half the cases, FCS will demonstrate a population of CD10+ BCL2+ often light chain restricted B-cells indistinguishable from what would be seen in an overt FL or DLBCL, meaning that caution must be exercised in using these studies to make the diagnosis of lymphoma particularly when only dealing with cytologic preparations.
Unfortunately routine histologic/immunohistologic evaluations do not predict which cases are associated with overt FL/DLBCL. The critical factors that lead to the development of overt lymphomas in patients with FLBUS and practical ways of detecting them in face of the focal nature of the abnormal follicles remain to be established. Because not all antibodies are run in the same tubes, numbers are not all comparable to one another.
a. Based on CD19 and/or CD20 b. There are 2.3% lambda restricted CD10+ BCL2+ B--cells with slightly dimmer CD20 compared to the other CD10+ B--cells that are BCL2--, have dimmer CD10 and brighter CD20. c. Based on CD5, there was no CD3 stain. d. Based on CD20. There were more numerous CD19+ cells related to technical aspects. 
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